Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.12.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Koen M Klomberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: k.m.klomberg@…. Hauptthemen laut MEDLINE: Multiple Myeloma, Melphalan, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Groningen.
Abstract (Originalsprache)
BACKGROUND: High dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) remains the preferred consolidation strategy for patients with newly diagnosed multiple myeloma (MM). While its use has expanded to patients over 65 years (> 65), few studies have compared real-world outcomes to younger patients. PATIENTS AND METHODS: This retrospective cohort study included patients with MM who received first line HDT/ASCT between 2013 and 2022 at a large tertiary referral center in The Netherlands. We compared outcomes between patients > 65 years and 65 years or younger (≤ 65), assessing overall survival (OS), time to next treatment or MM-related death (TTNT-D), complications, and quality of life. RESULTS: Among 394 patients, 109 were > 65 years (range 66-72, 11 patients > 70) and 285 ≤ 65 years (range 34-65). Distributions in baseline characteristics were comparable. Median OS and TTNT-D were 101 and 41 months, respectively, in patients > 65 years compared to 116 (P = .56) and 38 (P = .78) months for patients ≤ 65 years. Age was not a significant predictor. HDT/ASCT was feasible, illustrated by a low serious complications incidence rate and a transplantation-related mortality of 1%. Quality of life data show a stable to increasing trend in the long term. CONCLUSION: Survival, treatment response, complication rates, and long-term quality of life were comparable between age groups. Our real-world data confirm the safety and efficacy of HDT/ASCT in fit patients with MM over 65 years. These findings support the broader application of HDT/ASCT in selected older patients and reinforce its role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: k.m.klomberg@umcg.nl.
- Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
Förderung
- University of Groningen
Zitieren
APA
Klomberg, K. M., Gelderloos, M., Kooistra, H. A. M., Nijland, M., de Bock, G. H., Huls, G. A., Brink, M., Roeloffzen, W. W. H., & Plattel, W. J. (2025). Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.007
Vancouver
Klomberg KM, Gelderloos M, Kooistra HAM, Nijland M, de Bock GH, Huls GA, et al. Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.007
BibTeX
@article{Klomberg2025,
author = {Klomberg, Koen M and Gelderloos, Miriam and Kooistra, Hilde A M and Nijland, Marcel and de Bock, Geertruida H and Huls, Gerwin A and Brink, Mirian and Roeloffzen, Wilfried W H and Plattel, Wouter J},
title = {Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.12.007}
}
EUVIMED